[go: up one dir, main page]

PL365779A1 - A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents

A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Info

Publication number
PL365779A1
PL365779A1 PL01365779A PL36577901A PL365779A1 PL 365779 A1 PL365779 A1 PL 365779A1 PL 01365779 A PL01365779 A PL 01365779A PL 36577901 A PL36577901 A PL 36577901A PL 365779 A1 PL365779 A1 PL 365779A1
Authority
PL
Poland
Prior art keywords
diabetes
treatment
combination
agents useful
antidiabetic agents
Prior art date
Application number
PL01365779A
Other languages
Polish (pl)
Inventor
Poelje Paul D. Van
Mark D. Erion
Toshihiko Fujiwara
Original Assignee
Metabasis Therapeutics, Inc.
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics, Inc., Sankyo Company, Limited filed Critical Metabasis Therapeutics, Inc.
Publication of PL365779A1 publication Critical patent/PL365779A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL01365779A 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes PL365779A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06

Publications (1)

Publication Number Publication Date
PL365779A1 true PL365779A1 (en) 2005-01-10

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365779A PL365779A1 (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (en)
JP (1) JP2004508297A (en)
KR (1) KR100854851B1 (en)
CN (2) CN101301294A (en)
AU (2) AU7327101A (en)
BR (1) BR0112212A (en)
CA (1) CA2412142A1 (en)
CZ (1) CZ20035A3 (en)
HU (1) HUP0301830A3 (en)
IL (2) IL153513A0 (en)
MX (1) MXPA02012713A (en)
NO (1) NO20030034L (en)
NZ (1) NZ523227A (en)
PL (1) PL365779A1 (en)
RU (1) RU2328308C2 (en)
SK (1) SK62003A3 (en)
WO (1) WO2002003978A2 (en)
ZA (1) ZA200300044B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
DE69910045T2 (en) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego NEW HETEROAROMATIC FRUCTOSE 1,6-BISPHOSPHATASE INHIBITORS
MXPA02008722A (en) 2000-03-08 2004-05-05 Metabasis Therapeutics Inc Novel aryl fructose 1,6 bisphosphatase inhibitors.
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
PL205971B1 (en) 2001-09-24 2010-06-30 Imp Innovations Ltd Modification of feeding behavior
EP1474163A2 (en) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
KR20070053764A (en) * 2004-08-18 2007-05-25 메타베이시스 테라퓨틱스, 인크. Novel Thiazole Inhibitors of Fructose 1,6-bisphosphatase
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (en) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Preparation produced by dry process
EP2089017A2 (en) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN103665043B (en) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 A kind of tenofovir prodrug and its application in medicine
TWI606848B (en) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
CN104788350A (en) * 2014-01-22 2015-07-22 天津大学 Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization
CN106831437B (en) * 2016-02-03 2019-06-21 华中师范大学 Ester type compound and its preparation method and application containing nitroethenyl group
CN114907285B (en) * 2021-02-10 2023-09-22 华中师范大学 Acylated saccharin compound, preparation method and application thereof, and hypoglycemic drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69014562T2 (en) * 1989-01-24 1995-06-22 Gensia Pharma METHOD AND COMPOUNDS FOR THE ADMINISTRATION OF AICA RIBOSIDES AND FOR THE REDUCTION OF THE BLOOD GLUCOSE CONTENT.
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) * 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.
CA2289621A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (fbpase)
DE69910045T2 (en) * 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego NEW HETEROAROMATIC FRUCTOSE 1,6-BISPHOSPHATASE INHIBITORS
ATE300288T1 (en) * 1998-12-24 2005-08-15 Metabasis Therapeutics Inc COMPOSITION CONTAINING INSULIN-SENSITIZING ACTIVE INGREDIENTS AND INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPASE) FOR THE TREATMENT OF DIABETES
ES2275654T5 (en) * 2000-01-21 2012-06-07 Novartis Ag Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
IL153513A0 (en) 2003-07-06
KR20030031952A (en) 2003-04-23
NZ523227A (en) 2005-04-29
NO20030034D0 (en) 2003-01-03
CN101301294A (en) 2008-11-12
HUP0301830A3 (en) 2007-10-29
BR0112212A (en) 2003-12-30
KR100854851B1 (en) 2008-08-27
CZ20035A3 (en) 2003-05-14
WO2002003978A3 (en) 2003-10-16
WO2002003978A2 (en) 2002-01-17
AU7327101A (en) 2002-01-21
CA2412142A1 (en) 2002-01-17
RU2328308C2 (en) 2008-07-10
CN100396283C (en) 2008-06-25
CN1599612A (en) 2005-03-23
JP2004508297A (en) 2004-03-18
ZA200300044B (en) 2004-05-06
SK62003A3 (en) 2003-09-11
AU2001273271B2 (en) 2006-01-05
NO20030034L (en) 2003-03-05
HUP0301830A2 (en) 2003-11-28
MXPA02012713A (en) 2004-09-10
IL153513A (en) 2014-07-31
EP1372660A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
AU7327101A (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0302950A3 (en) Synergistic herbicidal composition and a process for its use
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
GB9900416D0 (en) Inhibitors
HUP0301083A3 (en) Synergistical herbicide composition and use thereof
PL364904A1 (en) Thiohydantoins and use thereof for treating diabetes
GB0025782D0 (en) Use of inhibitors
HUP0402506A3 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
PL373301A1 (en) Phosphodiesterase 4 inhibitors
EP1337255A4 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
GB2361223B (en) Climbing appliance for roping-up and roping-down operations
GB0105613D0 (en) Pharmaceutically effective compounds and their use
EP1153022A4 (en) Prothease inhibitors
EP1222913A4 (en) Depilatories and agents for external use
HUP0204106A3 (en) Calcilytic compounds and process for their use
GB0202187D0 (en) "Inhibitors"
AU2001264273A1 (en) Amide compounds and use thereof
AU2001269496A1 (en) Surface treating agent for metal member
AUPQ582400A0 (en) A method of treatment and agents for use therein
GB0114572D0 (en) A method for the treatment of textile surfaces and compositions for use therein
HK1062634A (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0302212A3 (en) Fungicidal mixture based on amide compounds and its use
HUP0402141A3 (en) Herbicidal composition and process for its use
AU2002357594A1 (en) Nitrogen-containing heterocyclic compounds and use thereof

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)